Explore the frontier of life sciences and healthcare innovation. From breakthrough therapeutics and longevity research to the deep tech investments shaping tomorrow's treatments, discover the trends and breakthroughs redefining global health.
Sling Therapeutics closed a $123M Series C and dosed the first patients in a Phase 3 trial of linsitinib, an oral IGF-1R inhibitor for thyroid eye disease. The bet is convenience against the infused antibody class — and the readout is not due before 2028.
Generative AI has moved from designing molecules to designing entire viral genomes. Sixteen AI-designed phages worked in the lab, and NIAID is now funding three centers to turn phage design into medicine, while regulators work out how to oversee the same model.
Glidepath Health launched with backing from AlleyCorp and A-Squared Ventures and an exclusive license to Memorial Sloan Kettering's ImmunoChain technology. The company is betting that the operational logistics of cell and gene therapy, not the biology, now limit who gets treated.
A Dallas biotech left stealth with $15.5 million and a first-in-class candidate designed to lower blood alcohol in the emergency department. The preclinical number is striking. The human question is open.
The Berkeley- and New York-based longevity company is betting that returning an aged stem cell to its original developmental niche can improve bone-marrow transplants — and, later, target aging itself.
The FDA has accepted its first computational drug development tool, and C-Path has built a coalition to qualify the rest. The bottleneck in AI drug discovery is now evidence standards, not model accuracy.
The FDA cleared the first myostatin inhibitor on 11 September 2026. ISEMBYLD is an add-on for SMA at about $310,000 a year — but the real asset is Phase 2 data showing it preserves muscle during GLP-1 weight loss.
Encoded Therapeutics closed a $275 million Series F round to fund pivotal trials of its Dravet syndrome gene therapy. Phase 1/2 data are strong. The open question is how long a single dose lasts.